The case for & against
Bull & Bear analysis
Bullish
Precipio, Inc. (NASDAQ: PRPO) operates in the cancer diagnostics sector, specifically focused on providing rapid and accurate testing solutions through its proprietary laboratory services and innovative diagnostic products. The company has positioned itself strategically within the pathology space, emphasizing operational efficiencies, scalable operations, and a keen focus on meeting the growing demands for fast and reliable testing services. Precipio is navigating the complex healthcare landscape, contending with reimbursement dynamics and competition, while continuously working to enhance its product offerings and scale its operations.
Bull says
- ↑Q1 revenue $6.71M, up 30% YoY
- ↑Generated $60K operating cash flow, now self-sustaining
- ↑Lab capacity $24M annualized, scalable to $45–50M without capex
- ↑$10M annualized commercial pipeline underpins near-term growth
- ↑Gross margin around 40% with ongoing efficiency gains
- ↑Dividend yield 1.23% and strong balance sheet quality bolster resilience
Bear says
- ↓Adjusted EBITDA loss of $200K vs. +$960K prior quarter
- ↓Gross margin fell to 40% from 47% due to higher costs
- ↓Reimbursement changes shaved $125K off gross profit
- ↓Product revenue flat as customer demand remains volatile
- ↓Negative earnings yield and weak profitability factors weigh
- ↓Analysts cutting estimates, reflecting negative revisions outlook
Earnings Call · Q4 2022 · Mgmt. Guidance
Updated 05-21-2026bullish
Transcript signals
Bull points
- We believe that 2023 is going to be a very different year than 2022.
- In fact, already as initial evidence of that, we recently finished March with a record number of cases in the company's history and exceeded $1 million in cash collections in the same month.
- Moving to 2023, if I had to choose one word to describe the action goal for this year, that word is conversion.
Bear points
- We realized that penetrating labs, particularly after COVID, is not a simple task.
Read full transcript analysis ›